Please use this identifier to cite or link to this item: https://hdl.handle.net/10137/12252
Title: Study protocol: Australasian Registry of Severe Cutaneous Adverse Reactions (AUS-SCAR).
Authors: James F
Goh MSY
Mouhtouris E
Vogrin S
Chua KYL
Holmes NE
Awad A
Copaescu AM
De Luca JF
Zubrinich C
Gin D
Cleland H
Douglas A
Kern JS
Katelaris CH
Thien F
Barnes S
Yun J
Tong W
Smith WB
Carr A
Anderson T
Legg A
Bourke J
Mackay LK
Aung AK
Phillips EJ
Trubiano J
Citation: © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
BMJ Open. 2022 Aug 17;12(8):e055906. doi: 10.1136/bmjopen-2021-055906.
Abstract: INTRODUCTION: Severe cutaneous adverse reactions (SCAR) are a group of T cell-mediated hypersensitivities associated with significant morbidity, mortality and hospital costs. Clinical phenotypes include Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS) and acute generalised exanthematous pustulosis (AGEP). In this Australasian, multicentre, prospective registry, we plan to examine the clinical presentation, drug causality, genomic predictors, potential diagnostic approaches, treatments and long-term outcomes of SCAR in Australia and New Zealand. METHODS AND ANALYSIS: Adult and adolescent patients with SCAR including SJS, TEN, DRESS, AGEP and another T cell-mediated hypersensitivity, generalised bullous fixed drug eruption, will be prospectively recruited. A waiver of consent has been granted for some sites to retrospectively include cases which result in early mortality. DNA will be collected for all prospective cases. Blood, blister fluid and skin biopsy sampling is optional and subject to patient consent and site capacity. To develop culprit drug identification and prevention, genomic testing will be performed to confirm human leukocyte antigen (HLA) type and ex vivo testing will be performed via interferon-γ release enzyme linked immunospot assay using collected peripheral blood mononuclear cells. The long-term outcomes of SCAR will be investigated with a 12-month quality of life survey and examination of prescribing and mortality data. ETHICS AND DISSEMINATION: This study was reviewed and approved by the Austin Health Human Research Ethics Committee (HREC/50791/Austin-19). Results will be published in peer-reviewed journals and presented at relevant conferences. TRIAL REGISTRATION NUMBER: Australian New Zealand Clinical Trials Registry (ACTRN12619000241134).
Click to open Pubmed Article: https://www.ezpdhcs.nt.gov.au/login?url=https://www.ncbi.nlm.nih.gov/pubmed/35977774
Journal title: BMJ open
Volume: 12
Pages: e055906
Publication Date: 2022-08-17
Type: Clinical Trial Protocol
Journal Article
URI: https://hdl.handle.net/10137/12252
DOI: 10.1136/bmjopen-2021-055906
Orcid: 0000-0003-0469-5666
0000-0002-9183-5032
0000-0001-6541-5512
0000-0002-5111-6367
Appears in Collections:(a) NT Health Research Collection

Files in This Item:
There are no files associated with this item.


Items in ePublications are protected by copyright, with all rights reserved, unless otherwise indicated.

Google Media

Google ScholarTM

Who's citing

Pubmed

PubMed References

Who's citing